Verition Fund Management’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$800K Sell
9,000
-4,600
-34% -$473K 0.01% 1403
2025
Q4
$1.29M Sell
13,600
-15,000
-52% -$1.51M 0.01% 1956
2025
Q3
$2.82M Buy
28,600
+20,300
+245% +$2.17M 0.01% 1684
2025
Q2
$884K Buy
+8,300
New +$838K ﹤0.01% 2565

Other funds holding BNTX

Verition Fund Management's BNTX Position: Q1 2026 in Review

Verition Fund Management reduced its BioNTech (BNTX) stake by 32% in Q1 2026, selling an estimated $243K and leaving 5,126 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #1621.

Verition Fund Management first reported a position in BNTX in Q4 2020 and has held it in 6 quarters since. The position peaked at $1.93M in Q4 2024. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

  • Verition Fund Management held 5,126 shares of BioNTech worth $456K as of Q1 2026.
  • Verition Fund Management sold 2,364 BioNTech shares in Q1 2026, an estimated $243K.
  • BioNTech made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1621 holding.
  • Verition Fund Management first reported a position in BioNTech in Q4 2020 and has held it in 6 quarters since.
  • Verition Fund Management's BioNTech position peaked at $1.93M in Q4 2024.
  • 272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.